Proposed Regulation for Complementary Health Products in Singapore

HSA invites feedback on new regulatory framework for Complementary Health Products (CHP) under the Health Products Act.

Source updated: Jul 1, 2026

Primary source: Health Sciences Authority

PV Impact Brief

Urgency: HighConfidence: high

What changed

New mandatory safety reporting and record-keeping requirements for suppliers of Complementary Health Products (CHPs) in Singapore are proposed under the Health Products Act.

Why it matters

These requirements will strengthen the oversight of CHP products, ensuring better safety and quality standards which could impact compliance workflows for suppliers.

Action needed

Suppliers must implement new protocols for safety reporting and record-keeping as per the proposed framework.

Relevant for: Regulatory Intelligence LeadSignal Management LeadQPPV
Processes impacted: Country ComplianceSignal Management
Owner: Regulatory Intelligence Lead
Review cadence: Review before 2026-07-29.

Policy change details

Document type: Consultation
Policy status: consultation
Publication date: 2026-07-01
Consultation deadline: 2026-07-29
Policy change: HSA invites feedback on a proposed regulatory framework for Complementary Health Products (CHP) under the Health Products Act, aimed at strengthening oversight of product safety, quality, and duties of suppliers.

Key changes

Proposed requirements for Product Notification, Record Keeping, and Safety Reporting for CHPs.

Affected workflows

Country ComplianceSignal Management

PV impact

Suppliers of CHPs in Singapore may face new mandatory safety reporting and record-keeping requirements under the proposed framework.

View regulator source

Source document details

Extracted documents

Stakeholder Consultation on the Proposed Regulation for Complementary Health Products under the Health Products Acthtmlhtml · medium · 1 page

Unable to extract linked source document: https://www.googletagmanager.com/ns.html

Evidence and confidence

Confidence: highSource updated: Jul 1, 2026

Health Sciences Authority →Updated July 1, 2026

Full briefing

Practical implication

Suppliers must implement new protocols for safety reporting and record-keeping as per the proposed framework.

The Health Sciences Authority (HSA) of Singapore has opened a consultation on a proposed regulatory framework aimed at enhancing the safety and quality oversight of Complementary Health Products (CHP). This includes new mandatory requirements for Product Notification, Record Keeping, and Safety Reporting. The deadline for feedback is July 29, 2026.

What changed: New mandatory safety reporting and record-keeping requirements for suppliers of Complementary Health Products (CHPs) in Singapore are proposed under the Health Products Act.

Why it matters: These requirements will strengthen the oversight of CHP products, ensuring better safety and quality standards which could impact compliance workflows for suppliers.

Practical implication: Suppliers must implement new protocols for safety reporting and record-keeping as per the proposed framework.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Safety Signals #Consultation #Health Sciences Authority #reporting_requirement #policy-change #firecrawl-policy-agent

Related updates for your role

publicTherapeutics Goods Administration · Australia · Updated Jul 20, 2026

Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

Inspection ReadinessICSRRegulatory Intelligence Lead

SOP Impact2 SOPs

Relevant for: Regulatory Intelligence Lead, PV Quality Lead

verifiedRegulatory action: Notice

Read impact briefarrow_forward

publicMedicines and Healthcare products Regulatory Agency (MHRA) · United Kingdom · Updated May 23, 2026

MHRA confirms UK clinical trial safety reporting guidance is effective

Safety lead to: (1) perform a UK-clinical-trial safety reporting gap assessment against MHRA’s effective guidance sections (MedDRA coding; AE/SAE; RSI governance; SUSARs; annual safety reporting; USMs; serious breaches; temporary suspension), (2) update controlled SOPs/WIs and training records to reflect “effective” status as of 28 Apr 2026, and (3) document deviations/gaps and open CAPA where needed for ongoing UK trials and new submissions.

ICSRCountry ComplianceRegulatory Intelligence Lead

SOP Impact4 SOPs

Relevant for: Regulatory Intelligence Lead, QPPV

verifiedRegulatory action: Guidance

Read impact briefarrow_forward

publicEuropean Medicines Agency (EMA) · European Union · Updated Jul 20, 2026

CHMP Draft Agenda for Public Consultation on Thalassaemia and Sickle Cell Disease Guidelines

Sponsors and MAHs must review and align safety data collection and reporting protocols with the newly adopted guidelines while preparing for implementation of PRAC recommendations stemming from this meeting.

Signal ManagementICSRRegulatory Intelligence Lead

SOP Impact2 SOPs

Relevant for: Regulatory Intelligence Lead, Signal Management Lead

verifiedRegulatory action: Agenda

Read impact briefarrow_forward

publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead

SOP Impact1 SOPs

Relevant for: Regulatory Intelligence Lead, PV Quality Lead

verifiedRegulatory action: Checklist

Read impact briefarrow_forward